SCHEMBL16870533

SCHEMBL16870533

O=C(Nc1ccc(Oc2cccn3nccc23)c(F)c1)c1c(I)ccn(-c2ccc(F)cc2)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AXL P30530 19/20 1.00
MET P08581 9/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19562475 0.90 AXL (0.82) AXLMET
SCHEMBL16870461 0.87 AXL (1.00) AXLMET
SCHEMBL16870447 0.86 AXL (1.00) AXLMET
SCHEMBL16870537 0.86 AXL (1.00) AXLMET
SCHEMBL16863436 0.86 AXL (0.80) AXLMET
SCHEMBL16863328 0.85 AXL (0.73) AXLMET
SCHEMBL16870356 0.84 AXL (1.00) AXLMET
SCHEMBL14018126 0.84 AXL (0.95) AXLMET
SCHEMBL16870342 0.81 AXL (1.00) AXLMET
SCHEMBL22234273 0.80 MET (0.81) AXLMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148447-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE IGNYTA, INC. (US) 2018-05-31 US disclosed
EP-3309160-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE Ignyta, Inc. (US) 2018-04-18 EP disclosed
US-9914731-B2 Pyrazolo[1,5-a]pyridine derivatives and methods of their use IGNYTA, INC. (US) 2018-03-13 US disclosed
EP-3087070-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE IGNYTA INC (US) 2017-11-08 EP disclosed
US-20160318929-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE CEPHALON, INC. 2016-11-03 US disclosed
WO-2015100117-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE CEPHALON, INC. (US) 2015-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148447-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE AXL, FLT3, ERBB2 AXL 1/4885MET 10/4885
US-20160318929-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE AXL, FLT3, ERBB2 AXL 1/4885MET 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.